Compare Enveric Biosciences Inc (ENVB) vs Progressive Corp (PGR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enveric Biosciences Inc vs Progressive Corp — how do they compare? Enveric Biosciences Inc trades at $1.51 (market cap $6.80M), while Progressive Corp trades at $218.9 (market cap $126.95B). The key difference: Progressive Corp is far larger — about 18669.1× Enveric Biosciences Inc's market cap, and Progressive Corp pays a 0.18% dividend while Enveric Biosciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Enveric Biosciences Inc for 14 Days and Progressive Corp for 81 Days on average.
| ENVB | PGR | |
|---|---|---|
Market Cap | $6.80M | $126.95B |
Volume | 64,867 | 2,749,438 |
Sector | Health | Financials |
52-Week High | $10.80 | $242.16 |
52-Week Low | $1.27 | $190.40 |
Typical Hold Time | 14 Days | 81 Days |
Enterprise Value | -$1.49M | $135.16B |
Dividend Yield | — | 0.18% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.495 with a 1.7% daily gain, showing technical bearish signals despite recent earnings beats. The company reported no revenue in 2025 with significant losses (-$8.77M net income), though valuation metrics appear low (EV/EBITDA 0.17, P/B 0.84). Recent news highlights patent approvals and positive preclinical data for non-hallucinogenic therapeutics.
The outlook remains speculative given the lack of revenue and substantial losses, offset by strong analyst support (75% buy rating) and promising drug development progress. Key risks include funding needs and clinical trial outcomes, while institutional sentiment appears cautiously optimistic about long-term pipeline potential.
Progressive Corporation (PGR) trades at $214.12, up 0.98% with a bullish technical outlook. The stock shows strong fundamentals with revenue growing from $49.6B in 2022 to $87.6B in 2025 and net income reaching $11.3B. Valuation metrics appear reasonable with P/E of 10.74 and ROE of 34.94%. Recent earnings beat expectations in Q2 2026, and analyst consensus targets $222.23.
PGR presents a compelling investment case with consistent revenue growth and strong profitability. However, investors face risks from intensifying auto insurance competition and potential margin pressure. The stock's current price near resistance levels suggests limited near-term upside despite positive analyst sentiment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →About Progressive Corp
Progressive underwrites private and commercial auto insurance and specialty lines
Read more on PGR →
